Ask about this productRelated genes to: MRPL24 antibody
- Gene:
- MRPL24 NIH gene
- Name:
- mitochondrial ribosomal protein L24
- Previous symbol:
- -
- Synonyms:
- MRP-L18
- Chromosome:
- 1q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-02-28
- Date modifiied:
- 2014-11-19
Related products to: MRPL24 antibody
Related articles to: MRPL24 antibody
- Prostatic diseases, consisting of prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer (PCa), pose significant health challenges. While single-omics studies have provided valuable insights into the role of mitochondrial dysfunction in prostatic diseases, integrating multi-omics approaches is essential for uncovering disease mechanisms and identifying therapeutic targets. - Source: PubMed
Publication date: 2025/08/22
Gong BinbinYang FeixiangZhang NingWu ZhengyangLiu TianruiWang KunZhang XiangyuZhang YangyangSong ZhengyaoLiang Chaozhao - This study aims to identify and validate a transcriptomic signature capable of predicting the response to tumour necrosis factor inhibitors (TNFi) therapy in patients with rheumatoid arthritis (RA) before treatment initiation. - Source: PubMed
Publication date: 2025/09/03
Santiago-Lamelas LuciaCastro-Santos PatriciadeAndrés-Galiana Enrique JFernández-Martínez Juan LuisEscudero-Contreras AlejandroPérez-Sanchez CarlosSánchez-Pareja IsmaelLópez-Pedrera CharyJelinsky Scott ANikitsina MaryiaGonzalez-Alvaro IsidoroSobrín Raquel Dos SantosMera AntonioDurán JosefinaDíaz-Peña Roberto - Astaxanthin, a strong antioxidant carotenoid, has shown promising features in mitigating inflammation and oxidative stress and so that has been considered as a supplement for high-performance animals. In this study, we aimed to evaluate the effects of astaxanthin on oxidative stress, inflammation, and mitochondrial health in peripheral blood mononuclear cells (PBMC) isolated from Arabian racehorses. Horse-derived peripheral blood mononuclear cells exposed to hydrogen peroxide (H₂O₂) presented increased reactive oxygen species (ROS) accumulation and overexpression of pro-inflammatory cytokines such as IL-1β, IL-6, IFN-γ, and TNF-α. The addition of astaxanthin to cell culture reduced H₂O₂-induced inflammatory response by decreasing the expression levels of all the tested pro-inflammatory cytokines. Moreover, astaxanthin displayed a potential antioxidant response by increasing the expression of genes related to antioxidative defense, such as NRF1, SOD2, and GPX. Interestingly, PBMCs isolated from the horses orally supplemented with astaxanthin increased the expression of the mitophagy-related genes PINK1 and PARKIN. Moreover, genes related to mitochondrial dynamics and energy production, such as PPARGC1B, NDUFA9, and MRPL24, as well as genes associated with mitochondrial function, structure and dynamics, such as PIGBOS, MRLP24, PUSL1 and TFAM were upregulated in PBMCs isolated from astaxanthin supplemented horses. Altogether, these findings indicate that astaxanthin may be a beneficial dietary supplement for equine health, supporting resilience against oxidative stress and inflammatory challenges, and improving the recovery and performance of racing horses. - Source: PubMed
Publication date: 2025/04/26
Giercuszkiewicz-Hecold BeataPajuelo DavidSteczkiewicz ZofiaCywinska AnnaMarycz Krzysztof - The study aims to investigate the clinicopathological significance of MRPL24 in human cancers, with a particular focus on breast cancer (BC). Comprehensive bioinformatics analyses were conducted using data from The Cancer Genome Atlas (TCGA) and various advanced database, including cBioPortal, UALCAN, TIMER, Prognoscan, TISIDB, KM Plotter, and The Human Protein Atlas, to provide a detailed evaluation of MRPL55's role in cancer. The findings were further validated through experimental studies. Pan-cancer analysis of TCGA/ICGC data revealed significant amplification of MRPL24 across multiple cancer types, with the highest amplification rate of 60% observed in metastatic breast cancer. MRPL24 was found to be overexpressed in primary breast tumors, metastatic, and various molecular subtypes of breast cancer. High MRPL24 expression was associated with poor prognosis and lower survival rates in breast cancer patients. RT-PCR and western blot confirmed MRPL24 depletion in breast cancer cells. Knockdown of MRPL24 was shown to suppress proliferation, and clonogenic potential in breast cancer cells and inhibit cell migration. Additionally, MRPL24 depletion sensitized breast cancer cells to PD0325901 and 5-FU treatment. Mechanistic studies revealed that MRPL24 knock-down downregulates mRNA levels of oncogenic genes, including c-MYC, BRD4, WNT3, and STAT3. Positive correlations were observed between MRPL24 and key genes involved in ferroptosis regulation, such as ERBB2, ERBB3, GRB2, PIK3CA, AKT1, MAPK3, and MAPK1. Finally, through virtual screening and molecular dynamics simulations, we have identified three FDA-approved drugs with strong binding affinities and interactions with MRPL24. These findings underscore MRPL24's oncogenic role in breast cancer and suggest potential therapeutic strategies targeting this protein. - Source: PubMed
Publication date: 2025/01/09
Khan Abdul JamilKhan Islam UddinMan ShadLiu ShihaoAilun GaowaAbbas ManzarZhang Feng - This study aimed to improve personalized treatment strategies and predict survival outcomes for patients with uveal melanoma (UM). - Source: PubMed
Zhang XiaoqianJin LingZhou ChenchenLiu JinghuaJiang Qin